1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63605FB6497AC897885256E9F004CB9E3
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-staffing-spend-maximizing-value-decreasing-cost?opendocument
18
19opendocument
2044.192.49.72
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Structure, Staffing and Budgets

Medical Affairs Staffing & Spend: Maximizing Value, Decreasing Cost

DB Image

ID: 4631


Features:

Metrics, Graphics


Pages/Slides: 20


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

With new pressures and regulations, pharmaceutical companies are looking for more ways then ever to decrease the cost of maintaining their medical affairs department, mostly through staffing and expenditure. By finding the optimal level of staffing and spending to achieve efficiency and effectiveness, companies can save money while maintaining a high-value medical affairs function. Medical affairs leaders can use the information in this 6-page document to learn how top companies find the optimal level of staffing and spending to achieve both efficiency and effectiveness in executing the mission of medical affairs.

Key Topics

  • Key Drivers of Staffing and Spending
  • Overall Medical Affairs Staffing Levels
  • Segmentation of Medical Affairs Staffing by Capabilities
  • Staffing Ratios: FTEs to US Sales
  • Planned Staffing Change and Drivers
  • External Spend: Average and Range
  • Factors Driving High Resource Consumption
  • Source and Distribution of Medical Affairs External Spend

Methodology
This document originated from Best Practices, LLC benchmarking research conducted on behalf of a client. It contains metrics as well as graphics.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device


Companies Profiled:
Abbott; Sanofi-aventis; Amgen; AstraZeneca; Eli Lilly; Schering-Plough; Janssen; Roche; Merck; GlaxoSmithKline

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.